🕷️
SetupAI
EN
🔥較早收集於 5m

2026 AI 生物製藥授權交易升溫

2026 AI 生物製藥授權交易升溫
PostLinkedIn
🔥閱讀原文： 36氪
#ai-biotech#bd-licensing#bci-ipoinsilico-medicineinsilico-medicineastrazenecaneucyber

💡AI drug startups at $3B vals snag 50% global BD—prime opps for AI biotech devs.

⚡ 30-Second TL;DR

有什麼變化

逾百家醫療企業排港股 IPO；Pre-IPO 融資對沖風險，估值 3-5 億美元。

為什麼重要

驗證 AI 加速藥物發現，開啟自免等領域 BD 機會。投資者青睞有授權實績平台。

下一步行動

Target MNC BD for your AI-generated CNS or metabolism candidates using Insilico-like platforms.

誰應關注：Founders & Product Leaders

關鍵要點

  • •逾百家醫療企業排港股 IPO；Pre-IPO 融資對沖風險，估值 3-5 億美元。
  • •中國 BD 交易佔全球 50%，MNC 熱情不減但價格上漲。
  • •英矽智能等 AI 製藥獲授權；某新創估值 30 億美元。
  • •腦機介面熱潮，博睿康、強腦科技衝刺 IPO，估值超 45 億元。
  • •熱門非腫瘤領域：自免、代謝、中樞；GLP-1 迭代口服劑型。

🧠 深度解析

背景與延伸：來自公開資料，非原文內容。引用 9 個來源。

🔑 增強重點摘要

  • •Insilico Medicine listed on the Hong Kong Stock Exchange in December 2025, raising approximately $290-293 million USD.[1][4][5][9]
  • •Insilico secured a collaboration with Servier in early 2026 for oncology drug discovery using Pharma.AI, with total potential value up to $888 million including $32 million upfront and early milestones.[5]
  • •Insilico received a $5 million milestone payment from Menarini in late 2025 or early 2026 for first-in-patient dosing in Phase 1 of MEN2501 (ISM9682), a KIF18A inhibitor for cancers with chromosome instability.[6]
  • •Insilico has software licensing agreements with 13 of the world's top 20 multinational pharmaceutical companies, alongside research collaborations with Fosun Pharma and Sanofi involving upfront payments of tens of millions.[2][3][7]

🔮 前景展望AI analysis grounded in cited sources

Insilico's Pharma.AI platform will secure at least two additional out-licensing deals exceeding $100 million by end of 2026
The company's recent deals with Qilu ($120M), Servier ($888M), and prior out-licensing totaling over $2B with Exelixis and Menarini demonstrate accelerating momentum in AI-driven partnerships.[2][5]
AI biopharma BD deals in China will exceed 60% global market share by mid-2026
China already claims 50% of global BD deals with rising MNC interest and valuations, fueled by firms like Insilico achieving frequent high-value partnerships.[1][2]

⏳ 時間線

2021
Qilu begins using Insilico’s PandaOmics platform, laying groundwork for expanded collaboration.[3]
2025-01
Insilico out-licenses ISM9682 (MEN2501) to Menarini Group.[6]
2025-07
Insilico receives $3 million development milestone from Menarini.[6]
2025-12
Insilico Medicine lists on Hong Kong Stock Exchange, raising ~$290M.[1][4][5][9]
2026-01
Insilico signs $888M oncology collaboration with Servier using Pharma.AI.[5]
2026-01
Insilico and Qilu announce $120M partnership for cardiometabolic small molecule inhibitors.[2][3][7]
🔥閱讀原文： 36氪
📰

AI 週報

閱讀本週精選 AI 大事摘要 →

👉相關動態

同主題

探索 #ai-biotech

同產品

更多關於 insilico-medicine

同來源

最新來自 36氪

AI 策展新聞聚合。所有內容版權歸原始發布者所有。
原始來源： 36氪 ↗

這是摘要，不是原文。去看原站，或訂閱每週簡報。

每週 AI 簡報

每週一封，可隨時退訂。